Combination of p300 and csf β-amyloid(1-42) assays may provide a potential tool in the early diagnosis of alzheimer's disease

Current Alzheimer Research

Volumn 7, Issue 4, 2010, Pages 295-299

  Papaliagkas, V T ^a   Anogianakisa, G ^a   Tsolaki, M N ^a   Koliakos, G ^a   Kimiskidis, V K ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

amyloid(1 42); Alzheimer's disease; Auditory event related potentials; Mild cognitive impairment; P300 amplitude; P300 latency

Indexed keywords

AMYLOID BETA PROTEIN[1-42];

AGED; ALZHEIMER DISEASE; AMPLITUDE MODULATION; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; EARLY DIAGNOSIS; EVOKED AUDITORY RESPONSE; FEMALE; FOLLOW UP; HUMAN; LATENT PERIOD; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ACOUSTIC STIMULATION; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AUDITORY PATHWAYS; CEREBRAL CORTEX; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVENT-RELATED POTENTIALS, P300; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SPINAL PUNCTURE;

EID: 77954008188     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510791162421     Document Type: Article

References (27)

1. Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 107: 165-173 (2005).
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984).
3. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736 (1987).
4. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82: 4245-4249 (1985).
5. Strozyk D, Blennow K, White LR, Launer LJ. CSF Ab42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60: 652-656 (2003).
6. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56: 673-680 (1999).
7. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55: 937-945 (1998).
8. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF β-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9: 705-710 (2004).
9. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234 (2006).
10. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59: 1729-1734 (2002).
11. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289: 2094-2103 (2003).
12. Bennys K, Portet F, Touchon J, Rondouin G. Diagnostic value of event-related evoked potentials N200 and P300 subcomponents in early diagnosis of Alzheimer's disease and mild cognitive impairment, J Clin Neurophysiol 24: 405-412 (2007).
13. Papaliagkas VT, Kimiskidis VK, Tsolaki MN, Anogianakis G. Usefulness of event-related potentials in the assessment of mild cognitive impairment. BMC Neurosci 9: 107 (2008).
14. Yamaguchi S, Knight RT. P300 generation by novel somatosensory stimuli. Electroencephalogr Clin Neurophysiol 78: 50-55 (1991).
15. Golob EJ, Irimajiri R, Starr A. Auditory cortical activity in amnestic mild cognitive impairment: relationship to subtype and conversion to dementia. Brain 130: 740-752 (2007).
16. Frodl T, Hampel H, Juckel G, Bürger K, Padberg F, Engel RR, et al. Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology 39: 175-181 (2002).
17. Golob EJ, Johnson JK, Starr A. Auditory event-related potentials during target detection are abnormal in mild cognitive impairment. Clin Neurophysiol 113: 151-161 (2002).
18. Irimajiri R, Golob EJ, Starr A. Auditory brain-stem, middle- and long-latency evoked potentials in mild cognitive impairment. Clin Neurophysiol 116: 1918-1929 (2005).
19. Polich J. P300 in clinical applications. In Electroencephalography: basic principles, clinical applications and related fields. Niedermayer E, Lopes de la Silva, Eds. Baltimore-Munich: Urban F, Schwartzenberger, p.1073-1091 (1999).
20. Folstein M, Folstein S, McHugh P. 'Mini-mental state' a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
21. Fountoulakis K, Tsolaki M, Chantzi H, Kazis A. Mini-Mental State Examination (MMSE): a validation study in the Greek elderly population. Encephalos (Greece) 31: 93-102 (1994).
22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-308 (1999).
23. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol 10: 119-128 (2003).
24. Schoonenboom NS, Mulder C, Vanderstichele H, Pijnenburg YA, Van Kamp GJ, Scheltens P, et al. Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid. Clin Chem 51: 1057-1060 (2005).
25. Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelsø C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 47: 1776-1781 (2001).
26. Papaliagkas VT, Anogianakis GA, Tsolaki MN, Koliakos G, Kimiskidis VK. Prediction of Conversion from mild cognitive impairment to Alzheimer's disease by CSF cytochrome c levels and N200 latency. Curr Alzheimer Res 6: 279-284 (2009).
27. Papaliagkas VT, Anogianakis G, Tsolaki MN, Koliakos G, Kimiskidis VK. Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels. Dement Geriatr Cogn Disord 28: 30-35 (2009).